188 related articles for article (PubMed ID: 37533611)
21. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
22. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
[TBL] [Abstract][Full Text] [Related]
23. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
24. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.
Truong SR; Barry WT; Moslehi JJ; Baker EL; Mayer EL; Partridge AH
Oncologist; 2016 Jun; 21(6):666-70. PubMed ID: 27107002
[TBL] [Abstract][Full Text] [Related]
26. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
[TBL] [Abstract][Full Text] [Related]
27. [Cardiotoxicity as undesired side effect in the treatment of breast cancer].
Gramatyka M
Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100
[TBL] [Abstract][Full Text] [Related]
28. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
Kalam K; Marwick TH
Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
[TBL] [Abstract][Full Text] [Related]
29. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
30. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
31. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
32. Anemia Profiles in Cancer Patients: Prevalence, Contributing Factors, and Insights From a Retrospective Study at a Single Cancer Center in Saudi Arabia.
Badheeb AM; Ahmed F; Badheeb MA; Obied HY; Seada IA; Al Jumman A; Alyami NH; Elhadi M; Almakrami AH; Mokhtar I
Cureus; 2023 Jul; 15(7):e42400. PubMed ID: 37621805
[TBL] [Abstract][Full Text] [Related]
33. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
34. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
35. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.
Sheppard RJ; Berger J; Sebag IA
Front Pharmacol; 2013; 4():19. PubMed ID: 23487556
[TBL] [Abstract][Full Text] [Related]
37. Incidence of trastuzumab-induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center.
Al-Saleh K; Abdel-Warith A; Alghamdi M; Aldiab A; Ali A; Alsaeed EF; Abozeed WN; Abdel-Aziz N
Mol Clin Oncol; 2022 Apr; 16(4):78. PubMed ID: 35251629
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity profile of trastuzumab.
Ewer SM; Ewer MS
Drug Saf; 2008; 31(6):459-67. PubMed ID: 18484781
[TBL] [Abstract][Full Text] [Related]
39. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
Guglin M; Krischer J; Tamura R; Fink A; Bello-Matricaria L; McCaskill-Stevens W; Munster PN
J Am Coll Cardiol; 2019 Jun; 73(22):2859-2868. PubMed ID: 31171092
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]